ADOCIA Patent applications |
Patent application number | Title | Published |
20150250858 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 - A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin. | 09-10-2015 |
20150231160 | RAPID-ACTING INSULIN FORMULATION COMPRISING AN OLIGOSACCHARIDE - A composition in aqueous solution, including an insulin and at least one oligosaccharide whose average degree of polymerization is between 3 and 13 and whose polydispersity index PDI is above 1.0, the oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. | 08-20-2015 |
20140235536 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS COMPRISED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS - A composition in the form of an injectable aqueous solution, the pH of which is from 6.6 to 7.8, comprises at least:
| 08-21-2014 |
20130245246 | POLYSACCHARIDES COMPRISING CARBOXYL FUNCTIONAL GROUPS SUBSTITUTED BY A HYDROPHOBIC ALCOHOL DERIVATIVE - A polysaccharide comprising carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical:
| 09-19-2013 |
20130231281 | Rapid acting insulin formulation comprising an oligosaccharide - A composition in aqueous solution, including an insulin and at least one oligosaccharide whose average degree of polymerization is between 3 and 13 and whose polydispersity index PDI is above 1.0, the oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. | 09-05-2013 |
20130178415 | Injectable solution at pH 7 comprising at least one basal insulin the PI of which is between 5.8 and 8.5 and a substituted co-polyamino acid - A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone. | 07-11-2013 |
20130065826 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 - A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin. | 03-14-2013 |
20120309680 | Functionalized oligosaccharides - The invention relates to an oligodextran, chosen from dextrans whose average degree of polymerization is less than 10, modified by at least one substituent of general formula I: | 12-06-2012 |
20120295833 | Polysaccharides having an adjustable degree of functionalization - An anionic polysaccharide comprising carboxylic acid functional groups of formula I: | 11-22-2012 |
20120094902 | Fast-acting insulin formulation - A complex between an insulin and a polysaccharide comprising carboxyl functional groups is described, the polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, the phenylalanine derivative being chosen from phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and the insulin being either a human insulin or an insulin analog. A pharmaceutical composition including at least one complex, especially in the form of an injectable solution, is also described. | 04-19-2012 |
20120041079 | DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS - Dextran of the following general formula I: | 02-16-2012 |
20110301086 | Complex polymere amphiphile-PDGF - Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups. | 12-08-2011 |
20110195913 | Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer - Anionic polysaccharide derivatives partially functionalized by at least two vicinal hydrophobic groups, the hydrophobic groups, which are identical or different, being carried by an at least trivalent radical or spacer, a method of synthesis of the functionalized polysaccharides, and pharmaceutical compositions having one of the polysaccharides and at least one active principle are provided. | 08-11-2011 |
20110178011 | Polysaccharide/BMP complexes which are soluble at physiological pH - A complex of a polysaccharide and recombinant human BMP-2 and BMP-7, soluble at physiological pH, wherein the polysaccharide/BMP mass ratio is less than 15, the polysaccharide being selected from the group of polysaccharides having carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical. | 07-21-2011 |
20110172166 | Anionic polysaccharides functionalized by a hydrophobic acid derivative - A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to pharmaceutical compositions including them. | 07-14-2011 |
20110159068 | Osteogenic composition comprising a growth factor/amphiphilic polymer complex, a soluble cation salt and an organic support - An open implant constituted of an osteogenic composition comprising at least one osteogenic growth factor/amphiphilic anionic polysaccharide complex, one soluble salt of a cation at least divalent, and one organic support, said organic support comprising no demineralized bone matrix. In one embodiment, said implant is in the form of a lyophilizate. It also relates to the method for the preparation thereof. | 06-30-2011 |
20110112039 | Polysaccharides comprising carboxyl functional groups substituted via esterification by a hydrophobic alcohol - Polysaccharide including carboxyl functional groups. The polysaccharide being chosen from the group of anionic synthetic polysaccharides including 1,6 bonds obtained from neutral polysaccharides of which at least one of a carboxyl functional groups is esterified by a hydrophobic alcohol (-Ah) (residue of a hydrophobic alcohol). The hydrophobic alcohol (Ah) being grafted or bonded to the anionic polysaccharide by a function F (ester function), which results from coupling between the carboxylate function of the anionic polysaccharide and hydroxyl function of the hydrophobic alcohol. Carboxyl functions of anionic polysaccharide, which are not substituted, are in the form of carboxylate of a cation. The polysaccharide including carboxyl functional groups are amphiphilic at neutral pH. | 05-12-2011 |
20110027363 | Nouvelle forme d'administration de proteines osteogeniques - Osteogenic compositions are formed from a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, the coprecipitate being in divided form. A process for preparing the coprecipitate in divided form contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products, kits and medical devices comprising the coprecipitate. | 02-03-2011 |
20110014189 | Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents - A stable pharmaceutical composition with at least one monoclonal antibody and at least one amphiphilic polysaccharide chosen from the group of amphiphilic polysaccharides comprising carboxylate functional groups partly substituted with at least one hydrophobic substituent is disclosed. | 01-20-2011 |
20100305035 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative - The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above. | 12-02-2010 |
20100249020 | Fast-acting insulin formulation - The invention relates to a complex between an insulin and a polysaccharide comprising carboxyl functional groups, said polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, said phenylalanine derivative being chosen from the group consisting of phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters, and said insulin being either a human insulin or an insulin analog. The invention also relates to a pharmaceutical composition comprising at least one complex according to the invention, especially in the form of an injectable solution. | 09-30-2010 |
20100190709 | Angiogenic composition - The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic. | 07-29-2010 |
20100184965 | Complex consisted of a polysaccharide and an HBP - The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs. | 07-22-2010 |
20100167991 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative - The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above. | 07-01-2010 |
20100167984 | Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation - The invention relates to a complex between human insulin and an amphiphilic polymer comprising carboxyl functional groups, said amphiphilic polymer being chosen from functionalized polysaccharides predominantly composed of glycoside monomers bonded via glycoside bonds of (1,6) type which are functionalized by at least one tryptophan derivative. | 07-01-2010 |
20100166867 | Novel administration form of osteogenic protein complexes - The invention relates to osteogenic compositions composed of a coprecipitate that contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide, said coprecipitate being in divided form. The invention also relates to kits for performing the invention. | 07-01-2010 |
20100137456 | Polysaccharides functionalized by tryptophan derivatives - The present invention relates to novel polysaccharide derivatives, predominantly comprising glycosidic bonds of (1,4), (1,3) and/or (1,2) type, functionalized by at least one tryptophan derivative. It also relates to processes for the synthesis thereof, to their uses as pharmaceutical excipient and to the pharmaceutical compositions comprising them. | 06-03-2010 |
20100009911 | Osteogenic synergic composition - The invention relates to an osteogenic synergic composition comprising at least one osteogenic growth factor, and at least one growth factor having a chemoattractant and angiogenic capacity. It also relates to the method for the preparation thereof and to the use thereof for the preparation and production of pharmaceutical products for use in bone reconstruction and regeneration, in the form of topical compositions, for example implants, pastes or gels. | 01-14-2010 |
20090305952 | Anionic polyamide functionalized with a tryptophan unit - The invention relates to an anionic polyamide functionalized with at least one tryptophan unit, -Trp, said tryptophan unit being linked to the polyamide by an amide function separated from the backbone by a linker arm, the polyamide being a chain selected from the group constituted of the following polymers: | 12-10-2009 |
20090291114 | OSTEOGENIC COMPOSITION COMPRISING A GROWTH FACTOR/AMPHIPHILIC POLYMER COMPLEX, A SOLUBLE CATION SALT AND AN ORGANIC SUPPORT - The invention relates to an open implant constituted of an osteogenic composition comprising at least:
| 11-26-2009 |
20090291113 | Osteogenic composition comprising a growth factor, a soluble cation salt and organic support - An open implant, and a method for preparing the implant, constituted of an osteogenic composition with at least one osteogenic growth factor, one soluble salt of a cation at least divalent, and one organic support. The organic support has no demineralized bone matrix. In one embodiment, the implant is in the form of a lyophilizate. | 11-26-2009 |
20090048412 | Complexes between an amphiphilic polymer and an osteogenic protein belonging to the family of BMPs - The invention relates to an amphiphilic-BMP polymer complex which is physically and chemically stable and soluble in water, characterised in that:
| 02-19-2009 |
20080293635 | Angiogenic composition - The present invention relates to a amphiphilic polymer in the preparation of a therapeutic composition for promoting angiogenesis at its site of administration, comprising a complex between a polymer and a PDGF, wherein the polymer is amphiphilic. | 11-27-2008 |
20080234227 | Dextran functionalized by hydrophobic amino acids - The invention relates to a dextran functionalized by at least one hydrophobic alpha-amino acid radical, said alpha-amino acid being grafted or bonded to the dextran by a bonding arm and a functional group. A hydrophobic amino acid radical is understood as being the product of coupling between the amine of the amino acid and an acid carried by the bonding arm, said dextran being amphiphilic at neutral pH. In an embodiment, the hydrophobic amino acid is selected from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide, 2-indole ethyl-amine and their alkaline cation salts. The present invention relates also to a pharmaceutical composition comprising one of the dextrans according to the invention. | 09-25-2008 |